Clinical Trial Update: A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) [Phase 1, Phase 2]

View source ↗

Summary

A master protocol to evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) across Phase 1 and Phase 2 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• DCC-3009

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 1, Phase 2 | Status: RECRUITING